Wave Life Sciences is trading at $3.86, up +6.04% in pre-market, with the reason for the move unclear.
- No new company-specific announcement dated September 30 was found.
- Recent news includes starting a Phase 2a combination trial of WVE-007 with tirzepatide and appointing Monika Vnuk as chief business officer. Both were announced earlier and neither establishes a fresh catalyst for this morning’s move.
- Provided market indicators are mixed and do not show a broad-market move likely to explain the gain.